What is NTRA's five-year median EV/Sales?

9.8x. Half of NTRA's weekly readings since February 2022 were higher and half were lower. This page has 494 weekly readings, from May 8, 2017 to Oct 19, 2026.

Does a low historical rank mean a stock is a buy?

No. The rank compares NTRA only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Natera Inc (NTRA) valuation history

Health Care

$403.95

Latest weekly close · Market cap $57.9B

Historically high

As of Oct 24, 2026

NTRA's EV/Sales of 21.0x is higher than 99% of its weekly readings since February 2022.

Weekly EV/Sales since February 2022

EV/Sales each weekMiddle half of its readingsMedian 9.8×

Median: 9.8×
Low to high: 3.8×–21.5×
Versus median: +114%
History starts: February 2022

EV/Sales

99thpercentile

of its weekly readings since February 2022

Historically high

Growth, last 12 months vs the year before

Revenue: +38%accelerating
EPS: n/a

Price vs revenue and EPS, indexed to 100

Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends. EPS was not positive in this window, so it is left out.

PriceRevenue, last 12 months100 = first reading

EV/Sales at each year-end

The last weekly reading of each year, and its percentile against the five years before it.

NTRA EV/Sales at each year-end
Year-end	EV/Sales	5-year percentile
Dec 29, 2025	14.4×	97
Dec 30, 2024	13.0×	99
Dec 25, 2023	6.4×	76
Dec 26, 2022	4.4×	30
Dec 27, 2021	n/a	Too little history
Dec 28, 2020	n/a	Too little history
Dec 30, 2019	7.4×	83
Dec 31, 2018	n/a	Too little history
Dec 25, 2017	1.9×	7

Health Care peers on EV/Sales

Each percentile compares a stock with its own last five years.

Compare NTRA with peers

Health Care peers of NTRA on EV/Sales
Stock	EV/Sales	Versus its own history	5-year percentile
ABBVAbbVie	8.7×	Historically high	100
AMGNAmgen	7.5×	Historically high	96
ARWRArrowhead Pharmaceuticals Inc	11.1×	Below its usual range	29
BBIOBridgebio Pharma Inc	21.5×	Below its usual range	24
BIIBBiogen	4.3×	Historically high	96

Appears in

Sector: Health Care
Screens: Stocks with Low P/E Ratios and Steady Revenue Growth
Stocks Below Their 5-Year Median P/E
Stocks Near Their Lowest P/E Ratios in 5 Years

Screen Health Care stocks the same way

Research on NTRA

No articles about NTRA yet. How valuation percentiles work

Loading peers and related research…

About this history

What is NTRA's current EV/Sales?: NTRA's EV/Sales of 21.0x is higher than 99% of its weekly readings since February 2022.
What is NTRA's five-year median EV/Sales?: 9.8x. Half of NTRA's weekly readings since February 2022 were higher and half were lower. This page has 494 weekly readings, from May 8, 2017 to Oct 19, 2026.
Does a low historical rank mean a stock is a buy?: No. The rank compares NTRA only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.